Abstract 1588P
Background
HZ infection is a potential cause of additional morbidity in immunocompromised patients (pts). ASCO, ESMO, and AIOM recommend recombinant zoster vaccine (RZV, Shingrix®, GSK) for pts who are immunocompromised due to cancer therapy. Vaccination rates among these pts remain suboptimal, and research on effective interventions to improve vaccination rates is limited. We report quality improvement interventions aimed at enhancing vaccine uptake among cancer outpatients.
Methods
A two-phase vaccination program for cancer outpatients receiving cancer treatments attending the Medical Oncology department of ASST Rhodense was conducted. Firstly, based on previous COVID-19 experience and with the collaboration of pts asociation La Lampada di Aladino ETS, a cross-sectional survey was administered to evaluate knowledge and awareness about HZ and RZV, vaccine hesitancy and the willingness of oncology pts to receive the RZV directly in the oncology department. Subsequently, an in-house vaccination program was managed by oncology staff.
Results
Two hundred pts conducted the survey while undergoing cancer treatment, highlighting partial understanding of HZ and RZV and a huge willingness to receive RZV from oncological staff. From June 2023 to April 2024, 220 pts received at least 1 dose of RZV, among which 152 (69%) received the second dose, resulting in a vaccination rate of 44% (220/496). Pts characteristics were as follows: 57% female, median age 70 (43-93) years, 80% ECOG PS 0-1, and 39% with at least 3 comorbidities. The most frequent tumors were breast 29%, lung 18%, colorectal 14%, prostate 10%, and upper GI 6%. The most common anticancer treatments were chemotherapy 44%, immunotherapy 28% targeted therapy 23%, and endocrine therapy 5%. No severe adverse event to RZV were reported. RZV was administered on average 7 (0-51) days before and 8 (0-70) days after intravenous therapy respectively.
Conclusions
Most cancer pts have a limited perception of the importance of vaccination. Vaccination with RZV was found to be safe. Our study highlights the potential for in-hospital vaccination strategies to enhance vaccination coverage and improve health outcomes among oncology pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
GSK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10